Safety and Efficacy of Erenumab for Migraine With and Without Aura

In a secondary analysis of data from randomized controlled trials, erenumab was effective and safe for migraine either with or without aura.

The effects of erenumab, a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor and used to treat migraine, are likely restricted to the periphery. To see whether erenumab is effective for migraine with aura, researchers compared the safety and efficacy of erenumab (70 mg or 140 mg) in a total of 2682 patients with migraine with and without aura in a post hoc secondary analysis of pooled data from double-blind, placebo-controlled randomized clinical trials. Three trials included adults with episodic migraine and one included adults with chronic migraine. Patients were excluded if they had significant vascular disease, and two studies excluded patients with uncontrolled hypertension.

Compared with baseline, both p…

Reviewing Author

Teshamae Monteith, MD

Disclosures

Consultant/Advisory BoardAbbVie; Axsome; Teva; Linpharma; e-Neura; Novartis; Merz; Lundbeck; Axsome; Pfizer. Unpaid co-author for collaborative research sponsored by AbbVie, Pfizer/Biohaven, and Theranica.

RoyaltiesSpringer

Editorial BoardsCephalalgia; Continuum Audio; Neurology Minute; Neurology; American Migraine Foundation; Brain and Life Magazine

Leadership Positions in Professional SocietiesFlorida Society of Neurology (member, Executive Board); American Migraine Foundation (member, Executive Board); United Councils of Neurologic Subspecialities Examination Committee (Vice Chair)

OtherPaid speaking/education for Medscape, Massachusetts Medical Society, American Headache Society, and American Academy of Neurology